BridgeBio Pharma Inc. (BBIO) Misses Q4 EPS by 7c

BridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q4 EPS of ($0.92), $0.07 worse than the analyst estimate of ($0.85). Revenue for the quarter came in at $1.87 million versus the consensus estimate of $5.01 million.

For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.

You May Also Be Interested In

• BridgeBio drug shows kidney benefits in heart disease study
• Elevance (ELV) PT Raised to $482 at Bernstein SocGen
• BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches